Amneal Pharmaceuticals (AMRX) vs Corcept Therapeutics (CORT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Amneal Pharmaceuticals (AMRX) has outperformed Corcept Therapeutics (CORT) over the past year, gaining 76.7% versus a loss of 17.7%. Over five years, AMRX leads with a +396.9% price change compared with +196.0% for CORT. Amneal Pharmaceuticals is the larger company by market cap ($7.36 billion vs $6.96 billion), about 1.1 times the size, while Corcept Therapeutics is growing revenue faster (+12.8% vs +8.0%).
On valuation, Corcept Therapeutics trades at a lower forward P/E (12.8x vs 17.1x for Amneal Pharmaceuticals). Corcept Therapeutics converts more of its revenue into profit, with a net margin of 13.1% versus 2.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRX | CORT |
|---|---|---|
| Share price | $21.12 | $63.62 |
| Market cap | $7.36B | $6.96B |
| 1-day change | -1.26% | -2.09% |
| YTD return | +67.62% | +82.82% |
| 1-year return | +76.74% | -17.69% |
| 5-year return | +396.94% | +196.04% |
| P/E ratio (TTM) | 52.80 | 47.83 |
| Forward P/E | 17.13 | 12.77 |
| EPS (TTM) | $0.40 | $1.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.02B | $761.41M |
| Revenue growth (YoY) | +8.05% | +12.79% |
| Net income (latest FY) | $72.06M | $99.65M |
| Gross margin | 36.88% | 98.30% |
| Operating margin | 13.05% | 5.88% |
| Net margin | 2.39% | 13.09% |
| 52-week high | $22.13 | $126.38 |
| 52-week low | $11.71 | $28.66 |
| Distance from 52-week high | -4.54% | -49.66% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +15.01% | +124.14% |
| Average volume | 3.16M | 1.26M |
| Shares outstanding | 348.41M | 109.44M |
| Employees | 8,700 | 730 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMRX has outperformed CORT by 94.4 percentage points over the past year.
- Corcept Therapeutics is more profitable, keeping 13.1 cents of every revenue dollar as net income versus 2.4 cents for Amneal Pharmaceuticals.
About Amneal Pharmaceuticals
AMRX stock →Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,700 employees
About Corcept Therapeutics
CORT stock →Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Health Care · Biotechnology: Pharmaceutical Preparations · 730 employees
AMRX vs CORT FAQ
Which is bigger, Amneal Pharmaceuticals or Corcept Therapeutics?
Amneal Pharmaceuticals (AMRX) is larger, with a market capitalization of $7.36B compared with $6.96B for Corcept Therapeutics (CORT).
Which stock has performed better over the past year, AMRX or CORT?
AMRX returned +76.74% over the past 12 months, compared with -17.69% for CORT (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, AMRX or CORT?
CORT has the lower trailing P/E at 47.8, versus 52.8 for AMRX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Amneal Pharmaceuticals and Corcept Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.